1. Patients Excluded from Study
600 pts with 644 eyes accessed for eligibility
78 pts with 122 eyes excluded
522 pts included in study each contributing 1 eye
44 bilateral pts with each eye group D or E
30 pts received extensive pre-enucleation treatment
2 pts had non-tumor enucleation
2 pts died from chemo toxicity
1 anterior chamber hemorrhage?
1 atrophy w/o chemo
3 plaque
6 PPV
17 pts with IAC
2 radio
1 stem cell
Factors to consider: pathologic staging, time from diagnosis to enu, neoadjuvant chemo, adjuvant chemo
Dependent variable: mortality.
1 immunotherapy

2. Mortality and Pathology of Patients with D eyes
600 pts with 644 eyes accessed for eligibility
78 pts with 122 eyes excluded
522 pts included in study each contributing 1 eye
180 D eyes
342 E eyes
120 neoadjuvant chemo
60 no neoadjuvant chemo
5 dead (4.2%)
14 lost (11.7%)
0 dead (0%)
10 lost (16.7%)
103 (85%)
5 (4%)
2 (2%)
4 (3%)
3 (3%)
0 (0%)
pT1
pT2a
pT2b
pT3a
pT3b
pT3c
pT4
42 (70%)
7 (12%）
0 (0%）
0 (0%)
11 (18%)
Kruscal-Walis
Non-parametric test.

3. Mortality and Pathology of Patients with E eyes
600 pts with 644 eyes accessed for eligibility
78 pts with 122 eyes excluded
522 pts included in study each contributing 1 eye
342 E eyes
191 D eyes
128 neoadjuvant chemo
214 no neoadjuvant chemo
8 dead (3.7%)
27 lost (12.6%)
7 dead (5.5%)
28 lost (21.9%)
100 (78%)
5 (4%)
1 (1%)
11 (9%)
2 (1%)
4 (3%)
pT1
pT2a
pT2b
pT3a
pT3b
pT3c
pT4
126 (59%)
16 (7%)
5 (2%)
3 (1%)
52 (24%)
1 (1%)
12 (6%)

4. Relationship between neoadjuvant chemo cycle and pathology for staged D&E Eyes
Low Risk Pathology (LRP): pT1 and pT2
High Risk Pathology (HRP): pT3 and pT4

5. Relationship between neoadjuvant chemo cycle and mortality
After Controlling for Adjuvant Chemo
(Kaplan Mier Survival Analysis)